PMID- 36703739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Clinical study of lenvatinib in the treatment of hepatitis virus-related 
      hepatocellular carcinoma and antiviral therapy.
PG  - 1032881
LID - 10.3389/fphar.2022.1032881 [doi]
LID - 1032881
AB  - Background: Lenvatinib is recommended as a first-line tyrosine kinase inhibitor 
      for advanced hepatocellular carcinoma (HCC) since 2017. The aim of this study was 
      to compare the clinical action of lenvatinib in hepatitis B virus (HBV)-related 
      HCC and hepatitis C virus (HCV)-related HCC. Methods: A continuous cohort of 
      advanced HCC was retrospectively enrolled. And the patients were divided into 
      HBV-related HCC and HCV-related HCC based on previous history of hepatitis virus 
      infection. Then propensity score matching (PSM) was conducted to compare 
      objective response rate (ORR),disease control rate (DCR),progression-free 
      survival (PFS),overall survival (OS) and safety between the two groups. Results: 
      A total of 203 eligible patients were included, with 72 HBV-related HCC and 36 
      HCV-related HCC after PSM. Both ORR (20.8% vs. 5.6%, P = .0759) and DCR (76.4% 
      vs. 52.8%, P = .0232) were significantly higher in the HBV-related HCC than in 
      the HCV-related HCC. Although no statistical differences in PFS (6.1 months vs. 
      3.3 months, P = .17) and OS (14.9 months vs. 17.7 months, P = .96) were observed 
      between the two groups, there was a trend of difference in the PFS survival 
      curve. On multivariate regression analysis of PFS, both HBV infection (HR, .54; 
      95% CI, .31-.95; P = .0332) and antiviral time >5 years (HR, .49; 95% CI, .26-.9; 
      P = .0219) were identified as independent favorable factors, and AFP >200 ng/mL 
      (HR, 1.88; 95% CI, 1.1-3.22; P = .0216) were found to be an independent adverse 
      factor. In addition, compared with HCC who received the first dose of antiviral 
      drugs less than 5 years, the patients who were administered those drugs over 
      5 years had a significantly favorable PFS (11.27 months vs. 3.87 months, P = 
      .0011). Lenvatinib was well tolerated in all patients and the adverse events 
      (AEs) were similar between the two groups. Conclusion: It seemed that lenvatinib 
      benefited more in HBV-related advanced HCC in delaying disease progression, 
      compared to those with HCV-related advanced HCC.
CI  - Copyright (c) 2023 Li, Wang, Ding, Xu, Yu, Wu, Deng, Li and Chen.
FAU - Li, Xiaomi
AU  - Li X
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Jingyan
AU  - Wang J
AD  - Department of Interventional Radiology, The Fifth Medical Center, Chinese PLA 
      General Hospital, Beijing, China.
FAU - Ding, Xiaoyan
AU  - Ding X
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Xu, Yawen
AU  - Xu Y
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Yu, Minghua
AU  - Yu M
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wu, Hongxiao
AU  - Wu H
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Deng, Na
AU  - Deng N
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Chen, Jinglong
AU  - Chen J
AD  - Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20230110
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9871375
OTO - NOTNLM
OT  - antiviral therapy
OT  - hepatitis B virus
OT  - hepatitis C virus
OT  - hepatocellular carcinoma
OT  - lenvatinib
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/28 06:00
MHDA- 2023/01/28 06:01
PMCR- 2023/01/10
CRDT- 2023/01/27 02:15
PHST- 2022/09/12 00:00 [received]
PHST- 2022/12/30 00:00 [accepted]
PHST- 2023/01/27 02:15 [entrez]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/28 06:01 [medline]
PHST- 2023/01/10 00:00 [pmc-release]
AID - 1032881 [pii]
AID - 10.3389/fphar.2022.1032881 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Jan 10;13:1032881. doi: 10.3389/fphar.2022.1032881. 
      eCollection 2022.